peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

inhibitory hormone

Somatostatin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Octreotide acetate is stated to suppress pituitary secretion of thyroid stimulating hormone (TSH). Subcutaneous octreotide shows rapid, complete absorption; for a 100 mcg dose the reported Cmax is 5.2 ng/mL at 0.4 hours post-dose.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Pharmacokinetics

Subcutaneous octreotide shows rapid, complete absorption; for a 100 mcg dose the reported Cmax is 5.2 ng/mL at 0.4 hours post-dose.

Reported result
Peak concentrations of 5.2 ng/mL
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site. Peak concentrations of 5.2 ng/mL (100 mcg dose) were reached 0.4 hours after dosing.

    Rx OnlyPrescribing Information · CLINICAL PHARMACOLOGY

    dailymed:6b55eedd-4160-49f8-966b-55b0e60a4b06:97eb8c6215c1:97eb8c6215c1

What has been studied?

What the evidence says.

Study findings

Octreotide acetate is stated to suppress pituitary secretion of thyroid stimulating hormone (TSH).

Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Octreotide acetate suppresses secretion of thyroid stimulating hormone (TSH).

    Rx OnlyPrescribing Information · CLINICAL PHARMACOLOGY

    dailymed:6b55eedd-4160-49f8-966b-55b0e60a4b06:97eb8c6215c1:97eb8c6215c1

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
  • 12 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (8), assurance_score_below_0.72 (3), current_regulatory_source_required (2), extraction_ambiguity (12), high_risk_requires_regulatory_or_two_independent_sources (3), no_direct_support (11)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Rx OnlyPrescribing Information

    dailymed · published 2018-09-21 · retrieved 2026-09-01T08:37:10Z

Publication history and provenance

Version 3 · Automated assessment · 2026-09-01T08:37:10Z

116a981be02ad13c349975642ca3c54d9539c95ead66b00d26a9ca1b08f3cbb8